Cullinan adds first-in-class asset in hot NK cell checkpoint space
Via a deal with Avalon, Cullinan forms new single-asset unit with $26M series A to house anti-MICA mAb
The latest addition to Cullinan’s oncology portfolio is a mAb against MICA that’s set to become the first compound in the clinic against the NK cell target.
Through a deal announced on Thursday, Cullinan Oncology LLC formed its eighth single-asset subsidiary. The anti-MICA mAb was being developed at PDI Therapeutics Inc., a company created by Avalon Ventures as part of a build-to-buy arrangement with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).
Rather than acquiring PDI